The chronic and progressive nature of chronic obstructive pulmonary disease (COPD) is frequently marked by exacerbations, which are clinically defined as episodes of worsening respiratory symptoms such as dyspnea, cough, increased sputum production, and heightened sputum purulence. These exacerbations not only diminish the quality of life for individuals with COPD but also hasten disease advancement, potentially leading to hospitalization and death.
In observance of this November being COPD Awareness Month 2024, this article presents a comprehensive comparison of the current clinical practice guidelines from the Global Initiative for Chronic Obstructive Lung Disease (GOLD), the American Thoracic Society (ATS), and the American College of Chest Physicians (CHEST). By analyzing these recommendations, the goal is to provide healthcare providers with valuable insights and best practices for managing COPD exacerbations. This evidence-based approach aims to improve health outcomes for individuals affected by this complex condition.
Titles of Comparison:
| Titles | Global Strategy for Prevention, Diagnosis and Management of COPD: 2025 Report | Management of COPD Exacerbations | Prevention of Acute Exacerbations of COPD |
|---|---|---|---|
| Society | Global Initiative for Chronic Obstructive Lung Disease (GOLD) | American Thoracic Society (ATS) | American College of Chest Physicians (CHEST) |
| Publication Date | November 12, 2024 | March 01, 2017 | Publication: April 01, 2015 |
| Objective | Evidence-based strategy document for COPD diagnosis, management, and prevention, with citations from the scientific literature. | This document provides clinical recommendations for treatment of chronic obstructive pulmonary disease (COPD) exacerbations | In recognition of the importance of preventing exacerbations in patients with COPD, the American College of Chest Physicians (CHEST) and Canadian Thoracic Society (CTS) joint evidence-based guideline (AECOPD Guideline) was developed to provide a practical, clinically useful document to describe the current state of knowledge regarding the prevention of acute exacerbations according to major categories of prevention therapies. |
| Target Population | Developed for healthcare professionals based on the best scientific information available. | The target audience of this guideline is specialists in respiratory medicine who manage adults with COPD. General internists, primary care physicians, emergency medicine clinicians, other healthcare professionals and policy makers may also benefit from these guidelines | Developed a series of recommendations to assist clinicians in their management of the patient with COPD. |
| Methodology | The GOLD Science Committee reviews published research on COPD to evaluate the impact on recommendations including clinical trials, top medical journal and PubMed searches. | Comprehensive evidence syntheses, including meta-analyses, were performed to summarize all available evidence relevant to the Task Force’s questions. The evidence was appraised using the Grading of Recommendations, Assessment, Development and Evaluation approach and the results were summarized in evidence profiles. The evidence syntheses were discussed and recommendations formulated by a multidisciplinary Task Force of COPD experts | CHEST used recognized document evaluation tools to assess and choose the most appropriate studies and to extract meaningful data and grade the level of evidence to support the recommendations in each PICO question in a balanced and unbiased fashion. |
| Graded Strength of Recommendations | Yes | Yes | Yes |
| Graded Level of Evidence | Yes | Yes | Yes |
| Systematic Review Conducted | Yes | Yes | Yes |
| Literature Review Conducted | Yes | Yes | Yes |
| COIs & Funding Source(s) Disclosed | Yes | Yes | Yes |
| Full-text | GLOBAL STRATEGY FOR PREVENTION, DIAGNOSIS AND MANAGEMENT OF COPD: 2025 Report | Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline | Prevention of Acute Exacerbations of COPD |
| Summary | Global Strategy for Prevention, Diagnosis and Management of COPD 2025 Report Summary | Prevention and Management of COPD Exacerbations Summary | Prevention of Acute Exacerbations of COPD Summary |
Management Overview
| GOLD (2025 Report) | ATS Management of COPD Exacerbations | CHEST’s Prevention of Acute Exacerbations of COPD | |
| Scope | Focus on both prevention and management of COPD exacerbations, with emphasis on long-term and acute care | Focuses on acute management of exacerbations, including decision-making for hospitalization and intensive care | Focuses on preventing exacerbations through long-term management strategies and lifestyle interventions |
| Pharmacologic Management | – Short-acting bronchodilators (SABA, SAMA) for symptom relief- Systemic corticosteroids (e.g., prednisone) for reducing inflammation – Antibiotics for bacterial infections if suspected- Long-acting bronchodilators (LABA, LAMA) for maintenance treatment- Consideration of biologics (e.g., dupilumab) for severe cases | – Short-acting beta-agonists (SABAs) and short-acting muscarinic antagonists (SAMAs) for bronchodilation – Systemic corticosteroids (e.g., prednisone) for anti-inflammatory treatment- Antibiotics if bacterial infection is suspected | – Inhaled corticosteroids (ICS) combined with LABAs or LAMAs for chronic management to reduce exacerbations – Systemic corticosteroids for acute exacerbations- Antibiotics based on clinical assessment (sputum color, purulence, or fever) |
| Use of Oxygen Therapy | Oxygen therapy for patients with severe hypoxemia or respiratory failure during exacerbations | Oxygen therapy for hypoxemic patients during exacerbations; titrate to target oxygen saturation (usually 88-92%) | Oxygen therapy for patients with chronic hypoxemia or frequent exacerbations, emphasizing long-term therapy for those with low oxygen levels |
| Antibiotics | Antibiotics recommended if there are signs of bacterial infection (e.g., increased sputum purulence, volume, or dyspnea) | – Antibiotics recommended for acute exacerbations with bacterial infection, particularly if symptoms are moderate to severe – Studies suggest that episodes that present with purulent sputum are most likely to benefit from antibiotic treatment | Antibiotics for exacerbations with clear clinical evidence of infection, often based on sputum characteristics |
| Hospitalization Criteria | Hospitalization recommended for severe exacerbations with respiratory failure or complicated exacerbations | Hospitalization indicated for patients with respiratory failure, inability to manage exacerbation at home, or failure of outpatient treatment | Focus on preventing hospitalizations by managing chronic conditions and reducing exacerbation frequency through long-term strategies |
| Non-Pharmacologic Management | – Pulmonary rehabilitation as an essential component for long-term management and recovery post-exacerbation – Patient education on recognizing exacerbation signs and seeking timely intervention | – Patient education on recognizing exacerbations and seeking timely treatment – Non-invasive ventilation (NIV) for patients with respiratory failure | – Pulmonary rehabilitation emphasized for reducing exacerbations and improving physical function – These recommendations do not support pulmonary rehabilitation for the prevention of rehospitalizations in patients with COPD greater than 4 weeks after a recent hospitalization – Smoking cessation and vaccination are key preventive strategies |
| Management of Respiratory Failure | Non-invasive ventilation (NIV) for patients with acute respiratory failure | Non-invasive ventilation (NIV) or mechanical ventilation for patients with respiratory failure | NIV may be recommended in chronic exacerbations that result in respiratory failure |
| Prevention of Future Exacerbations | Long-term strategies to reduce exacerbation frequency using maintenance inhalers (ICS, LABA, LAMA), pulmonary rehabilitation, and vaccinations | Less emphasis on long-term prevention, but early identification of exacerbations and proper management is key | Focus on long-term prevention using pharmacologic therapies, pulmonary rehabilitation, and addressing modifiable risk factors (e.g., smoking, physical inactivity) |
| Comorbidities | Comorbid conditions (e.g., cardiovascular disease, diabetes, anxiety, depression) are addressed as part of a holistic management approach | Acknowledges comorbidities but focuses more on managing the acute exacerbation | Comorbidities are managed in the context of long-term care, aiming to reduce exacerbation frequency and improve overall health |
| Role of Biologics | Consideration of biologic therapies like dupilumab for severe cases with eosinophilic inflammation or other specific indications | Biologics are generally not addressed in acute exacerbation management | Biologics are generally not addressed in the prevention of acute exacerbations, except for some specific indications like chronic eosinophilic inflammation |
Key Similarities:
- All three guidelines include the use of bronchodilators (SABAs, SAMAs) and systemic corticosteroids for managing acute exacerbations.
- Oxygen therapy is recommended for patients with severe hypoxemia.
- Antibiotics are suggested if bacterial infection is suspected in the exacerbation.
- Non-invasive ventilation (NIV) is considered for patients with respiratory failure.
- Patient education is emphasized to ensure early recognition of exacerbation symptoms.
Key Differences:
- GOLD (2025) offers the most comprehensive approach, combining acute management with long-term prevention strategies such as pulmonary rehabilitation and biologic therapies for specific cases.
- ATS is primarily focused on the acute phase, with hospitalization criteria and treatment of respiratory failure, while it offers less emphasis on long-term management and prevention.
- CHEST emphasizes preventing exacerbations through chronic management, such as long-term pharmacologic therapy, rehabilitation, and smoking cessation, while also addressing acute exacerbation management when necessary.
In conclusion, GOLD (2025) provides a more holistic, integrated approach that covers both acute exacerbation management and long-term prevention, while ATS is more focused on acute care and respiratory failure management, and CHEST targets prevention and long-term care strategies for reducing exacerbations.
Make sure to sign up for guideline alerts on guidelinecentral.com to stay up to date on all future side-by-side blogs and let us know if there is a topic you’d like to see compared on our next article!
Copyright © 2024 Guideline Central, All Rights Reserved.